<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-08-29" updated="2020-01-02">
  <drugbank-id primary="true">DB01627</drugbank-id>
  <name>Lincomycin</name>
  <description>An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.</description>
  <cas-number>154-21-2</cas-number>
  <unii>BOD072YW0F</unii>
  <average-mass>406.54</average-mass>
  <monoisotopic-mass>406.213757997</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>vet_approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Alexander D. Argoudelis, David W. Stroman, "Process of producing lincomycin nucleotides." U.S. Patent US4464466, issued June, 1972.</synthesis-reference>
  <indication>Lincomycin is an antibiotic used in the treatment of staphylococcal, streptococcal, and &lt;i&gt;Bacteroides fragilis&lt;/i&gt; infections.</indication>
  <pharmacodynamics>Lincomycin is a lincosamide antibiotic that produced by &lt;i&gt;Streptomyces lincolnensis&lt;/i&gt;. Lincomycin has been shown to be active in vitro against the following microorganisms: Aerobic gram-positive cocci: &lt;i&gt;Streptococcus pyogenes&lt;/i&gt; and &lt;i&gt;Viridans group streptococci&lt;/i&gt;; Aerobic gram-positive bacilli: &lt;i&gt;Corynebacterium diphtheriae&lt;/i&gt;; Anaerobic gram-positive non-sporeforming bacilli: &lt;i&gt;Propionibacterium acnes&lt;/i&gt;; Anaerobic gram-positive sporeforming bacilli: &lt;i&gt;Clostridium tetani&lt;/i&gt; and &lt;i&gt;Clostridium perfringens&lt;/i&gt;.</pharmacodynamics>
  <mechanism-of-action>Lincomycin inhibits protein synthesis in susceptible bacteria by binding to the 50 S subunits of bacterial ribosomes and preventing peptide bond formation upon transcription. It is usually considered bacteriostatic, but may be bactericidal in high concentrations or when used against highly susceptible organisms.</mechanism-of-action>
  <toxicity/>
  <metabolism>Presumed hepatic, however metabolites have not been fully characterized.</metabolism>
  <absorption>Rapidly absorbed from the gastrointestinal tract following oral administration. Approximately 20 to 30% absorbed orally in fasting state; absorption decreased when taken with food.</absorption>
  <half-life>The biological half-life after intramuscular or intravenous administration is 5.4 Â± 1.0 hours. The serum half-life may be prolonged in patients with severe impairment of renal function. Half life may be extended up to 2-fold in patients with hepatic impairment.</half-life>
  <protein-binding>Protein binding decreases with increased plasma concentrations. Range, 28 to 86% (average, 70 to 75%). Albumin is not thought to be the primary binding component.</protein-binding>
  <route-of-elimination>Urinary excretion after this dose ranges from 1.8 to 24.8 percent (mean: 3 percent). Biliary excretion is also an important route of excretion.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as proline and derivatives. These are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.</description>
    <direct-parent>Proline and derivatives</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic acids and derivatives</superclass>
    <class>Carboxylic acids and derivatives</class>
    <subclass>Amino acids, peptides, and analogues</subclass>
    <alternative-parent>Alpha amino acid amides</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monosaccharides</alternative-parent>
    <alternative-parent>Monothioacetals</alternative-parent>
    <alternative-parent>N-alkylpyrrolidines</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <alternative-parent>Oxanes</alternative-parent>
    <alternative-parent>Polyols</alternative-parent>
    <alternative-parent>Pyrrolidinecarboxamides</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Sulfenyl compounds</alternative-parent>
    <alternative-parent>Thioglycosides</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic heteromonocyclic compound</substituent>
    <substituent>Alpha-amino acid amide</substituent>
    <substituent>Amine</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Glycosyl compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monosaccharide</substituent>
    <substituent>Monothioacetal</substituent>
    <substituent>N-alkylpyrrolidine</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Organosulfur compound</substituent>
    <substituent>Oxacycle</substituent>
    <substituent>Oxane</substituent>
    <substituent>Polyol</substituent>
    <substituent>Proline or derivatives</substituent>
    <substituent>Pyrrolidine</substituent>
    <substituent>Pyrrolidine carboxylic acid or derivatives</substituent>
    <substituent>Pyrrolidine-2-carboxamide</substituent>
    <substituent>S-glycosyl compound</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Sulfenyl compound</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000109</drugbank-id>
      <name>Lincomycin hydrochloride</name>
      <unii>GCW8Y9936L</unii>
      <cas-number>859-18-7</cas-number>
      <inchikey>POUMFISTNHIPTI-BOMBIWCESA-N</inchikey>
      <average-mass>443.0</average-mass>
      <monoisotopic-mass>442.1904357</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001614</drugbank-id>
      <name>Lincomycin hydrochloride monohydrate</name>
      <unii>M6T05Z2B68</unii>
      <cas-number>7179-49-9</cas-number>
      <inchikey>LFZGYTBWUHCAKF-DCNJEFSFSA-N</inchikey>
      <average-mass>461.01</average-mass>
      <monoisotopic-mass>460.2010004</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">Cillimycin</synonym>
    <synonym language="english" coder="">LCM</synonym>
    <synonym language="spanish" coder="inn">Lincomicina</synonym>
    <synonym language="english" coder="usan">Lincomycin</synonym>
    <synonym language="french" coder="inn">Lincomycine</synonym>
    <synonym language="english" coder="inn">Lincomycinum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Lincocin</name>
      <labeller>Pharmacia and Upjohn Company LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0009-0555</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1964-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 mg/1mL</strength>
      <route>Intramuscular; Intravenous; Subconjunctival</route>
      <fda-application-number>NDA050317</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lincocin</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00030589</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1964-12-31</started-marketing-on>
      <ended-marketing-on>2006-08-02</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>500 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lincocin</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00030732</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1964-12-31</started-marketing-on>
      <ended-marketing-on>2016-05-06</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>300 mg</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lincomycin</name>
      <labeller>X-GEN Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>39822-0350</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 mg/1mL</strength>
      <route>Intramuscular; Intravenous; Subconjunctival</route>
      <fda-application-number>ANDA201746</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lincomycin</name>
      <labeller>X-GEN Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>39822-0353</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 mg/1mL</strength>
      <route>Intramuscular; Intravenous; Subconjunctival</route>
      <fda-application-number>ANDA201746</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lincomycin</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-4533</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 mg/1mL</strength>
      <route>Intramuscular; Intravenous; Subconjunctival</route>
      <fda-application-number>ANDA201746</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Lincobect</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Lincorex</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Lincocin</name>
      <ingredients>Lincomycin</ingredients>
    </mixture>
    <mixture>
      <name>Lincomycin</name>
      <ingredients>Lincomycin</ingredients>
    </mixture>
    <mixture>
      <name>Lincomycin</name>
      <ingredients>Lincomycin</ingredients>
    </mixture>
    <mixture>
      <name>Lincomycin</name>
      <ingredients>Lincomycin</ingredients>
    </mixture>
    <mixture>
      <name>Lincocin</name>
      <ingredients>Lincomycin</ingredients>
    </mixture>
    <mixture>
      <name>Lincocin</name>
      <ingredients>Lincomycin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Bimeda Inc.</name>
      <url>http://www.bimeda.com</url>
    </packager>
    <packager>
      <name>Carlisle Laboratories Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Clint Pharmaceutical Inc.</name>
      <url>http://www.clintpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Dispensing Solutions</name>
      <url>http://www.drxdispensing.com</url>
    </packager>
    <packager>
      <name>Keene Pharmaceuticals Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Llorens Pharmaceutical</name>
      <url>http://www.llorenspharm.com</url>
    </packager>
    <packager>
      <name>Martin Surgical Supply</name>
      <url/>
    </packager>
    <packager>
      <name>Medisca Inc.</name>
      <url>http://www.medisca.com</url>
    </packager>
    <packager>
      <name>Nord Ost Corp.</name>
      <url/>
    </packager>
    <packager>
      <name>Pharmacia Inc.</name>
      <url>http://www.pharmaciaupjohn.com</url>
    </packager>
    <packager>
      <name>Preferred Pharmaceuticals Inc.</name>
      <url>http://www.preferredpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Raz Co. Inc.</name>
      <url/>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Lincomycin hcl powder</description>
      <cost currency="USD">3.29</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Lincocin 300 mg/ml vial</description>
      <cost currency="USD">7.79</cost>
      <unit>ml</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Agents that produce neuromuscular block (indirect)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Anti-Bacterial Agents</category>
      <mesh-id>D000900</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antibacterials for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiinfectives for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Glycosides</category>
      <mesh-id>D006027</mesh-id>
    </category>
    <category>
      <category>Lincosamides</category>
      <mesh-id>D055231</mesh-id>
    </category>
    <category>
      <category>Macrolides, Lincosamides and Streptogramins</category>
      <mesh-id/>
    </category>
    <category>
      <category>Neurotoxic agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Protein Synthesis Inhibitors</category>
      <mesh-id>D011500</mesh-id>
    </category>
    <category>
      <category>Pyrrolidines</category>
      <mesh-id>D011759</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Enteric bacteria and other eubacteria</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>500 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Intravenous; Subconjunctival</route>
      <strength>300 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>300 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="J01FF02">
      <level code="J01FF">Lincosamides</level>
      <level code="J01F">MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS</level>
      <level code="J01">ANTIBACTERIALS FOR SYSTEMIC USE</level>
      <level code="J">ANTIINFECTIVES FOR SYSTEMIC USE</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>4wh5</pdb-entry>
    <pdb-entry>5hkv</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions>
    <food-interaction>Take on an empty stomach, food decreases absorption.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>The therapeutic efficacy of Succinylcholine can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine iodide</name>
      <description>The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium</name>
      <description>The therapeutic efficacy of Cisatracurium can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>The therapeutic efficacy of Rocuronium can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>The therapeutic efficacy of Doxacurium can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>The therapeutic efficacy of Mivacurium can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01245</drugbank-id>
      <name>Decamethonium</name>
      <description>The therapeutic efficacy of Decamethonium can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>The therapeutic efficacy of Metocurine can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>The therapeutic efficacy of Pancuronium can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>The therapeutic efficacy of Pipecuronium can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The therapeutic efficacy of Vecuronium can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>The therapeutic efficacy of Rapacuronium can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11156</drugbank-id>
      <name>Pyrantel</name>
      <description>The therapeutic efficacy of Pyrantel can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12989</drugbank-id>
      <name>Neosaxitoxin</name>
      <description>The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13295</drugbank-id>
      <name>Atracurium</name>
      <description>The therapeutic efficacy of Atracurium can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>The therapeutic efficacy of Gallamine can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13648</drugbank-id>
      <name>Alcuronium</name>
      <description>The therapeutic efficacy of Alcuronium can be increased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01575</drugbank-id>
      <name>Kaolin</name>
      <description>Kaolin can cause a decrease in the absorption of Lincomycin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09268</drugbank-id>
      <name>Picosulfuric acid</name>
      <description>The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The therapeutic efficacy of Erythromycin can be decreased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14022</drugbank-id>
      <name>Typhoid vaccine</name>
      <description>The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Doxycycline is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00256</drugbank-id>
      <name>Lymecycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00314</drugbank-id>
      <name>Capreomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00319</drugbank-id>
      <name>Piperacillin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Piperacillin is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00452</drugbank-id>
      <name>Framycetin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Framycetin is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00453</drugbank-id>
      <name>Clomocycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Clomocycline is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00512</drugbank-id>
      <name>Vancomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Vancomycin is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00560</drugbank-id>
      <name>Tigecycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Tigecycline is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00595</drugbank-id>
      <name>Oxytetracycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Oxytetracycline is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Chloroquine is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00618</drugbank-id>
      <name>Demeclocycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Demeclocycline is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium sulfate is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00684</drugbank-id>
      <name>Tobramycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Tobramycin is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Tetracycline is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00798</drugbank-id>
      <name>Gentamicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Gentamicin is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Quinidine is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00931</drugbank-id>
      <name>Metacycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Metacycline is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00955</drugbank-id>
      <name>Netilmicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Netilmicin is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00994</drugbank-id>
      <name>Neomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Neomycin is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Procainamide is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01082</drugbank-id>
      <name>Streptomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Streptomycin is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01111</drugbank-id>
      <name>Colistimethate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Colistimethate is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01172</drugbank-id>
      <name>Kanamycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Kanamycin is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01190</drugbank-id>
      <name>Clindamycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Clindamycin is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01219</drugbank-id>
      <name>Dantrolene</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Dantrolene is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01301</drugbank-id>
      <name>Rolitetracycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Rolitetracycline is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium oxide is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01378</drugbank-id>
      <name>Magnesium cation</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium cation is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01421</drugbank-id>
      <name>Paromomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Paromomycin is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03615</drugbank-id>
      <name>Ribostamycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Ribostamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04263</drugbank-id>
      <name>Geneticin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Geneticin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04626</drugbank-id>
      <name>Apramycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Apramycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04729</drugbank-id>
      <name>Gentamicin C1a</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Gentamicin C1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04808</drugbank-id>
      <name>Neamine</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Neamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06696</drugbank-id>
      <name>Arbekacin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Arbekacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06827</drugbank-id>
      <name>Viomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Viomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08437</drugbank-id>
      <name>Puromycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Puromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Magnesium hydroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Magnesium trisilicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09407</drugbank-id>
      <name>Magnesium chloride</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Magnesium chloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09409</drugbank-id>
      <name>Magnesium acetate tetrahydrate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Magnesium acetate tetrahydrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Magnesium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11110</drugbank-id>
      <name>Magnesium citrate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Magnesium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11189</drugbank-id>
      <name>Magnesium glycinate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Magnesium glycinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11230</drugbank-id>
      <name>Magnesium Aluminum Silicate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11512</drugbank-id>
      <name>Dihydrostreptomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Dihydrostreptomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11520</drugbank-id>
      <name>Hygromycin B</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Hygromycin B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12604</drugbank-id>
      <name>Sisomicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Sisomicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12615</drugbank-id>
      <name>Plazomicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Plazomicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13249</drugbank-id>
      <name>Magnesium silicate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Magnesium silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13264</drugbank-id>
      <name>Penimepicycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Penimepicycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13270</drugbank-id>
      <name>Dibekacin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Dibekacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13274</drugbank-id>
      <name>Micronomicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Micronomicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13359</drugbank-id>
      <name>Magnesium aspartate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Magnesium aspartate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13540</drugbank-id>
      <name>Isepamicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Isepamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13673</drugbank-id>
      <name>Bekanamycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Bekanamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13749</drugbank-id>
      <name>Magnesium gluconate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Magnesium gluconate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13786</drugbank-id>
      <name>Magnesium orotate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Magnesium orotate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13862</drugbank-id>
      <name>Magnesium phosphate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13996</drugbank-id>
      <name>Magnesium acetate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Magnesium acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00042</drugbank-id>
      <name>Botulinum Toxin Type B</name>
      <description>The risk or severity of adverse effects can be increased when Lincomycin is combined with Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00083</drugbank-id>
      <name>Botulinum toxin type A</name>
      <description>The risk or severity of adverse effects can be increased when Lincomycin is combined with Botulinum toxin type A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The risk or severity of adverse effects can be increased when Lincomycin is combined with Nicotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>The risk or severity of adverse effects can be increased when Lincomycin is combined with Mecamylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The risk or severity of adverse effects can be increased when Lincomycin is combined with Pentolinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The risk or severity of adverse effects can be increased when Lincomycin is combined with Trimethaphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>The risk or severity of adverse effects can be increased when Lincomycin is combined with Tubocurarine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08837</drugbank-id>
      <name>Tetraethylammonium</name>
      <description>The risk or severity of adverse effects can be increased when Lincomycin is combined with Tetraethylammonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The risk or severity of adverse effects can be increased when Lincomycin is combined with Hexamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08999</drugbank-id>
      <name>Cyclopentamine</name>
      <description>The risk or severity of adverse effects can be increased when Lincomycin is combined with Cyclopentamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The risk or severity of bleeding can be increased when Lincomycin is combined with Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The risk or severity of bleeding can be increased when Lincomycin is combined with Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Lincomycin is combined with Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The risk or severity of bleeding can be increased when Lincomycin is combined with Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The risk or severity of bleeding can be increased when Lincomycin is combined with Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The risk or severity of bleeding can be increased when Lincomycin is combined with 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The risk or severity of bleeding can be increased when Lincomycin is combined with Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The risk or severity of bleeding can be increased when Lincomycin is combined with (R)-warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The risk or severity of bleeding can be increased when Lincomycin is combined with Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The risk or severity of bleeding can be increased when Lincomycin is combined with Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The risk or severity of bleeding can be increased when Lincomycin is combined with Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The risk or severity of bleeding can be increased when Lincomycin is combined with Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The risk or severity of bleeding can be increased when Lincomycin is combined with Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Lincomycin is combined with (S)-Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00581</drugbank-id>
      <name>Lactulose</name>
      <description>The therapeutic efficacy of Lactulose can be decreased when used in combination with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>Reserpine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>Ziprasidone may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00260</drugbank-id>
      <name>Cycloserine</name>
      <description>Cycloserine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>Amitriptyline may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>Protriptyline may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>Vinorelbine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>Clozapine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00372</drugbank-id>
      <name>Thiethylperazine</name>
      <description>Thiethylperazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>Sulpiride may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>Loxapine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00409</drugbank-id>
      <name>Remoxipride</name>
      <description>Remoxipride may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>Promazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>Prochlorperazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>Teniposide may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>Droperidol may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>Imipramine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>Chlorpromazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>Haloperidol may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>Triflupromazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>Cyclophosphamide may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>Nortriptyline may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>Vincristine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>Amoxapine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>Fluphenazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00649</drugbank-id>
      <name>Stavudine</name>
      <description>Stavudine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>Thioridazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00680</drugbank-id>
      <name>Moricizine</name>
      <description>Moricizine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>Trimipramine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>Risperidone may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>Trifluoperazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>Perphenazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>Flupentixol may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>Ethanol may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00900</drugbank-id>
      <name>Didanosine</name>
      <description>Didanosine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>Cyclobenzaprine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>Mesoridazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01063</drugbank-id>
      <name>Acetophenazine</name>
      <description>Acetophenazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>Promethazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>Pimozide may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>Doxepin may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Desipramine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>Paclitaxel may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>Aripiprazole may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>Chlorprothixene may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>Clomipramine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01246</drugbank-id>
      <name>Alimemazine</name>
      <description>Alimemazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>Paliperidone may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01294</drugbank-id>
      <name>Bismuth subsalicylate</name>
      <description>Bismuth subsalicylate may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>Lithium cation may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>Methotrimeprazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01598</drugbank-id>
      <name>Imipenem</name>
      <description>Imipenem may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01608</drugbank-id>
      <name>Periciazine</name>
      <description>Periciazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>Acepromazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01615</drugbank-id>
      <name>Aceprometazine</name>
      <description>Aceprometazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01618</drugbank-id>
      <name>Molindone</name>
      <description>Molindone may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>Pipotiazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01622</drugbank-id>
      <name>Thioproperazine</name>
      <description>Thioproperazine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>Thiothixene may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>Zuclopenthixol may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>Lincomycin may increase the neurotoxic activities of Amineptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>Lincomycin may increase the neurotoxic activities of Fluspirilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04872</drugbank-id>
      <name>Osanetant</name>
      <description>Lincomycin may increase the neurotoxic activities of Osanetant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04888</drugbank-id>
      <name>Bifeprunox</name>
      <description>Lincomycin may increase the neurotoxic activities of Bifeprunox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>Lincomycin may increase the neurotoxic activities of Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05316</drugbank-id>
      <name>Pimavanserin</name>
      <description>Lincomycin may increase the neurotoxic activities of Pimavanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05687</drugbank-id>
      <name>BL-1020</name>
      <description>Lincomycin may increase the neurotoxic activities of BL-1020.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06016</drugbank-id>
      <name>Cariprazine</name>
      <description>Lincomycin may increase the neurotoxic activities of Cariprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06144</drugbank-id>
      <name>Sertindole</name>
      <description>Lincomycin may increase the neurotoxic activities of Sertindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>Lincomycin may increase the neurotoxic activities of Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06288</drugbank-id>
      <name>Amisulpride</name>
      <description>Lincomycin may increase the neurotoxic activities of Amisulpride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>Lincomycin may increase the neurotoxic activities of Lurasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>Lincomycin may increase the neurotoxic activities of Perospirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08927</drugbank-id>
      <name>Amperozide</name>
      <description>Lincomycin may increase the neurotoxic activities of Amperozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>Lincomycin may increase the neurotoxic activities of Dimetacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09000</drugbank-id>
      <name>Cyamemazine</name>
      <description>Lincomycin may increase the neurotoxic activities of Cyamemazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>Lincomycin may increase the neurotoxic activities of Butriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>Lincomycin may increase the neurotoxic activities of Brexpiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>Lincomycin may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>Lincomycin may increase the neurotoxic activities of Dosulepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09223</drugbank-id>
      <name>Blonanserin</name>
      <description>Lincomycin may increase the neurotoxic activities of Blonanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>Lincomycin may increase the neurotoxic activities of Melperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>Lincomycin may increase the neurotoxic activities of Zotepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09226</drugbank-id>
      <name>RP-5063</name>
      <description>Lincomycin may increase the neurotoxic activities of RP-5063.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Lincomycin may increase the neurotoxic activities of Methylene blue.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09275</drugbank-id>
      <name>Bismuth subcitrate potassium</name>
      <description>Lincomycin may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09286</drugbank-id>
      <name>Pipamperone</name>
      <description>Lincomycin may increase the neurotoxic activities of Pipamperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>Lincomycin may increase the neurotoxic activities of Tianeptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>Lincomycin may increase the neurotoxic activities of Oxaprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11281</drugbank-id>
      <name>Bismuth subcarbonate</name>
      <description>Lincomycin may increase the neurotoxic activities of Bismuth subcarbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11376</drugbank-id>
      <name>Azaperone</name>
      <description>Lincomycin may increase the neurotoxic activities of Azaperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11537</drugbank-id>
      <name>Pirlimycin</name>
      <description>Lincomycin may increase the neurotoxic activities of Pirlimycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11540</drugbank-id>
      <name>Propiopromazine</name>
      <description>Lincomycin may increase the neurotoxic activities of Propiopromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>Lincomycin may increase the neurotoxic activities of Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12273</drugbank-id>
      <name>Ecopipam</name>
      <description>Lincomycin may increase the neurotoxic activities of Ecopipam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>Lincomycin may increase the neurotoxic activities of Bromperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12518</drugbank-id>
      <name>Raclopride</name>
      <description>Lincomycin may increase the neurotoxic activities of Raclopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>Lincomycin may increase the neurotoxic activities of Ritanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12710</drugbank-id>
      <name>Perazine</name>
      <description>Lincomycin may increase the neurotoxic activities of Perazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12867</drugbank-id>
      <name>Benperidol</name>
      <description>Lincomycin may increase the neurotoxic activities of Benperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>Lincomycin may increase the neurotoxic activities of Opipramol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12958</drugbank-id>
      <name>Prothipendyl</name>
      <description>Lincomycin may increase the neurotoxic activities of Prothipendyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13025</drugbank-id>
      <name>Tiapride</name>
      <description>Lincomycin may increase the neurotoxic activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>Lincomycin may increase the neurotoxic activities of Amitriptylinoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13209</drugbank-id>
      <name>Bismuth subnitrate</name>
      <description>Lincomycin may increase the neurotoxic activities of Bismuth subnitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13213</drugbank-id>
      <name>Butaperazine</name>
      <description>Lincomycin may increase the neurotoxic activities of Butaperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>Lincomycin may increase the neurotoxic activities of Dibenzepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>Lincomycin may increase the neurotoxic activities of Quinupramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13256</drugbank-id>
      <name>Clothiapine</name>
      <description>Lincomycin may increase the neurotoxic activities of Clothiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13273</drugbank-id>
      <name>Sultopride</name>
      <description>Lincomycin may increase the neurotoxic activities of Sultopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13382</drugbank-id>
      <name>Chlorproethazine</name>
      <description>Lincomycin may increase the neurotoxic activities of Chlorproethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>Lincomycin may increase the neurotoxic activities of Melitracen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13403</drugbank-id>
      <name>Oxypertine</name>
      <description>Lincomycin may increase the neurotoxic activities of Oxypertine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>Lincomycin may increase the neurotoxic activities of Lofepramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13420</drugbank-id>
      <name>Thiazinam</name>
      <description>Lincomycin may increase the neurotoxic activities of Thiazinam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>Lincomycin may increase the neurotoxic activities of Iprindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13523</drugbank-id>
      <name>Veralipride</name>
      <description>Lincomycin may increase the neurotoxic activities of Veralipride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13552</drugbank-id>
      <name>Trifluperidol</name>
      <description>Lincomycin may increase the neurotoxic activities of Trifluperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13554</drugbank-id>
      <name>Moperone</name>
      <description>Lincomycin may increase the neurotoxic activities of Moperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13557</drugbank-id>
      <name>Thiopropazate</name>
      <description>Lincomycin may increase the neurotoxic activities of Thiopropazate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>Lincomycin may increase the neurotoxic activities of Diethyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13665</drugbank-id>
      <name>Fluanisone</name>
      <description>Lincomycin may increase the neurotoxic activities of Fluanisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13676</drugbank-id>
      <name>Mosapramine</name>
      <description>Lincomycin may increase the neurotoxic activities of Mosapramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>Lincomycin may increase the neurotoxic activities of Imipramine oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13784</drugbank-id>
      <name>Dixyrazine</name>
      <description>Lincomycin may increase the neurotoxic activities of Dixyrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>Lincomycin may increase the neurotoxic activities of Penfluridol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13841</drugbank-id>
      <name>Clopenthixol</name>
      <description>Lincomycin may increase the neurotoxic activities of Clopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13909</drugbank-id>
      <name>Bismuth subgallate</name>
      <description>Lincomycin may increase the neurotoxic activities of Bismuth subgallate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13910</drugbank-id>
      <name>Valproate bismuth</name>
      <description>Lincomycin may increase the neurotoxic activities of Valproate bismuth.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>Lincomycin may increase the neurotoxic activities of Aripiprazole lauroxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14651</drugbank-id>
      <name>Perphenazine enanthate</name>
      <description>Lincomycin may increase the neurotoxic activities of Perphenazine enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00781</drugbank-id>
      <name>Polymyxin B</name>
      <description>Lincomycin may increase the neurotoxic activities of Polymyxin B.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>0.5</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.1</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>2.93e+01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-0.32</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>atovaquone</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>406.54</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>406.213757997</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H][C@]1(C[C@@H](CCC)CN1C)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C18H34N2O6S</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>OJMMVQQUTAEWLP-KIDUDLJLSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>122.49</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>102.67</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>43.65</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>12.37</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>7.97</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>logP</kind>
      <value>0.56</value>
      <source>HANSCH,C ET AL. (1995)</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>8553</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>8552</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>6472</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>3000540</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46506668</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C06812</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00223</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>2272112</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50335522</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164749212</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>3QB</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000839</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Lincomycin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1447</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/lincocin.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/lincomycin.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP0000728</smpdb-id>
      <name>Lincomycin Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00117</drugbank-id>
          <name>Histidine</name>
        </drug>
        <drug>
          <drugbank-id>DB00131</drugbank-id>
          <name>Adenosine phosphate</name>
        </drug>
        <drug>
          <drugbank-id>DB00134</drugbank-id>
          <name>Methionine</name>
        </drug>
        <drug>
          <drugbank-id>DB00149</drugbank-id>
          <name>L-Leucine</name>
        </drug>
        <drug>
          <drugbank-id>DB00156</drugbank-id>
          <name>L-Threonine</name>
        </drug>
        <drug>
          <drugbank-id>DB00160</drugbank-id>
          <name>L-Alanine</name>
        </drug>
        <drug>
          <drugbank-id>DB00161</drugbank-id>
          <name>L-Valine</name>
        </drug>
        <drug>
          <drugbank-id>DB00167</drugbank-id>
          <name>Isoleucine</name>
        </drug>
        <drug>
          <drugbank-id>DB00171</drugbank-id>
          <name>ATP</name>
        </drug>
        <drug>
          <drugbank-id>DB00172</drugbank-id>
          <name>Proline</name>
        </drug>
        <drug>
          <drugbank-id>DB00174</drugbank-id>
          <name>Asparagine</name>
        </drug>
        <drug>
          <drugbank-id>DB01627</drugbank-id>
          <name>Lincomycin</name>
        </drug>
        <drug>
          <drugbank-id>DB01972</drugbank-id>
          <name>Guanosine-5'-Monophosphate</name>
        </drug>
        <drug>
          <drugbank-id>DB02431</drugbank-id>
          <name>Cytidine-5'-Triphosphate</name>
        </drug>
        <drug>
          <drugbank-id>DB03685</drugbank-id>
          <name>Uridine monophosphate</name>
        </drug>
        <drug>
          <drugbank-id>DB03929</drugbank-id>
          <name>D-Serine</name>
        </drug>
        <drug>
          <drugbank-id>DB04160</drugbank-id>
          <name>Pyrophosphoric acid</name>
        </drug>
      </drugs>
      <enzymes/>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000743</id>
      <name>50S ribosomal protein L10</name>
      <organism>Shigella flexneri</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A12807</ref-id>
            <pubmed-id>1527036</pubmed-id>
            <citation>Odom OW, Hardesty B: Use of 50 S-binding antibiotics to characterize the ribosomal site to which peptidyl-tRNA is bound. J Biol Chem. 1992 Sep 25;267(27):19117-22.</citation>
          </article>
          <article>
            <ref-id>A12808</ref-id>
            <pubmed-id>10856379</pubmed-id>
            <citation>Champney WS, Tober CL: Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol. 2000 Aug;41(2):126-35.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P0A7J6" source="Swiss-Prot">
        <name>50S ribosomal protein L10</name>
        <general-function>Structural constituent of ribosome</general-function>
        <specific-function>Protein L10 is also a translational repressor protein. It controls the translation of the rplJL-rpoBC operon by binding to its mRNA (By similarity).Forms part of the ribosomal stalk, playing a central role in the interaction of the ribosome with GTP-bound translation factors.</specific-function>
        <gene-name>rplJ</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.51</theoretical-pi>
        <molecular-weight>17711.38</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="623">Shigella flexneri</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AE005674</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>24054563</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P0A7J6</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>RL10_SHIFL</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010523|50S ribosomal protein L10
MALNLQDKQAIVAEVSEVAKGALSAVVADSRGVTVDKMTELRKAGREAGVYMRVVRNTLL
RRAVEGTPFECLKDAFVGPTLIAYSMEHPGAAARLFKEFAKANAKFEVKAAAFEGELIPA
SQIDRLATLPTYEEAIARLMATMKEASAGKLVRTLAAVRDAKEAA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010524|50S ribosomal protein L10 (rplJ)
ATGGCTTTAAATCTTCAAGACAAACAAGCGATTGTTGCTGAAGTCAGCGAAGTAGCCAAA
GGCGCGCTGTCTGCAGTAGTTGCGGATTCCCGTGGCGTAACTGTAGATAAAATGACTGAA
CTGCGTAAAGCAGGTCGCGAAGCTGGCGTATACATGCGTGTTGTTCGTAACACCCTGCTG
CGCCGTGCTGTTGAAGGTACTCCGTTCGAGTGCCTGAAAGACGCGTTTGTTGGTCCGACC
CTGATTGCATACTCTATGGAACACCCGGGCGCTGCTGCTCGTCTGTTCAAAGAGTTCGCG
AAAGCGAATGCAAAATTTGAGGTCAAAGCCGCTGCCTTTGAAGGTGAGCTGATCCCGGCG
TCTCAGATCGACCGCCTGGCAACTCTGCCGACCTACGAAGAAGCAATTGCACGCCTGATG
GCAACCATGAAAGAAGCTTCGGCTGGCAAACTGGTTCGTACTCTGGCTGCTGTACGCGAT
GCGAAAGAAGCTGCTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00466</identifier>
            <name>Ribosomal_L10</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>ribosome</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>large ribosomal subunit rRNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>structural constituent of ribosome</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of translation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ribosome biogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>translation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>